Table 1.
Overview of the currently available literature.
| Author | Study title details | Type of study | Country | Number of patients | Improvement in hemodynamics | Improvement in oxygenation | Control of inflammatory response | Reference number from manuscript |
|---|---|---|---|---|---|---|---|---|
| Alharthy A | Continuous Renal Replacement Therapy with the Addition of CytoSorb® Cartridge in Critically Ill Patients with COVID‐19 plus Acute Kidney Injury: a Case‐Series. Artificial Organs 2021; 45(5):E101-112 | Retrospective case series | Saudi Arabia | 50 | Yes | Yes | 31 | |
| Berlot G | Effects of Tocilizumab Versus Hemoadsorption Combined with Tocilizumab in Patients with SARS-CoV-2 Pneumonia: Preliminary Results. Int J Artif organs 2021; epub | Retrospective case series | Italy | 2 | Yes | Yes | 51 | |
| Rieder M et al. | Cytokine Adsorption in Patients with Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation. Crit Care 2020; 24: 435 | Randomized control trial—Interim analysis | Germany | 4 vs 4 | Yes | 55 | ||
| Rampino T et al. | Hemoperfusion with CytoSorb as Adjuvant Therapy in Critically Ill Patients with SARS-CoV2 Pneumonia. Blood Purif 2020; epub | Retrospective case series | Italy | 5 of 9 consecutive pts treated with CytoSorb | Yes | Yes | 56 | |
| Lebreton G et al. | Longitudinal Cytokine Profiling in Severe COVID-19 Patients on ECMO and Hemoadsorption. AJRCCM 2021; 203(11): 1433–5 | Prospective case series | France | 11 consecutive patients on CytoSorb compared to 11 noncontemporaneous pts | Yes | 57 | ||
| Ferrer R | Regain control of Inflammation – IL6 Blockers or CytoSorb (or both)? Presented at “the trinity of COVID-19: Immunity, Inflammation and Intervention Webinar,” May 20th 2020. | Webinar presentation of retrospective patients | Spain | 7 | Yes | Yes | 59 | |
| Moazami N | CytoSorb: First Clinical Experience in the USA. Presented at the “EuroELSO Virtual ECMO Day,” June 25th 2020 | Webinar presentation of retrospective patients | USA | 10 vs 10 | Yes | Yes | 65 | |
| Nassiri AA | Blood Purification with CytoSorb in Critically Ill COVID-19 Patients: A Case Series of 26 Patients. Artif Org 2021; epub | Retrospective case series | Iran | 26 | Yes | Yes | Yes | 66 |
| Peng Z | Safety and Feasibility of CytoSorb Therapy in COVID-19 Patients–the Wuhan Experience. Presented at the “Cytokine Adsorption in Severely Ill COVID-19 Patients” Webinar. April 16th 2020. | Webinar presentation of retrospective patients | China | 10 | Yes | Yes | Yes | 69 |
| Nierhaus A | Rationale for the Use of CytoSorb in COVID-19 Patients. Presented at the “7th International CytoSorb Users' Meeting” Webinar. 29th Oct 2020 | Webinar presentation of preliminary RCT results | Germany | 5 vs 5 | Yes | Yes | 70 | |
| Lopez-Almarez J | CytoSorb Therapy in COVID-19 Patients. Experiences from Latin America. Presented at the “7th International CytoSorb Users' Meeting” Webinar. 29th Oct 2020 | Webinar presentation of retrospective patients | Latin America | 25 | Yes | Yes | Yes | 71 |
| Riva I | Its More than Cytokine Removal, Presented at the “Cytokine Adsorption in Severely Ill COVID-19 Patients” | Webinar presentation of retrospective patients | Italy | 11 vs 10 | Yes | Yes | 68 |